This brand name is authorized in United States
The drug DYRENIUM contains one active pharmaceutical ingredient (API):
|
1
Triamterene
UNII WS821Z52LQ - TRIAMTERENE
|
|
Triamterene is a potassium-sparing agent. Triamterene inhibits the reabsorption of sodium ions in exchange for potassium and hydrogen ions at that segment of the distal tubule under the control of adrenal mineralocorticoids (especially aldosterone). The fraction of filtered sodium reaching this distal tubular exchange site is relatively small, and the amount which is exchanged depends on the level of mineralocorticoid activity. Thus, the degree of natriuresis and diuresis produced by inhibition of the exchange mechanism is necessarily limited. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| DYRENIUM Capsule | FDA, National Drug Code (US) | MPI, US: SPL/Old |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C03DB02 | Triamterene | C Cardiovascular system → C03 Diuretics → C03D Potassium-sparing agents → C03DB Other potassium-sparing agents |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: US | FDA, National Drug Code | Identifier(s): 59212-002, 59212-003 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
